Oxford BioMedica Announces Exercise of Option by ImaginAb
— ImaginAb acquires exclusive worldwide licence for 5T4-based imaging diagnostic — Oxford, UK and Los Angeles, CA – 29 November 2012: Oxford BioMedica (“Oxford… Read More
Oxford BioMedica Announces Ocular Clinical Programme Update
— Positive DSMB review of first patient cohort in UshStat® Phase I/IIa Study —— Further encouraging data from RetinoStat® and StarGen™ clinical studies —… Read More
Oxford BioMedica Interim Management Statement November 2012
Oxford, UK 14 November 2012: Oxford BioMedica (“Oxford BioMedica” or “the Company”) (LSE:OXB), the leading gene-based biopharmaceutical company, today publishes its interim management statement for the period from 1 July to 13 November 2012. Read More
Oxford BioMedica Announces Issue of Key US Patent Relating to RNA Interference Using Lentiviral Vector Technology
– Leading intellectual property position further strengthened — Oxford, UK – 9 November 2012: Oxford BioMedica (“Oxford BioMedica” or “the Company”) (LSE:OXB), the… Read More
Oxford BioMedica Announces Update on TroVax® Development Strategy
Oxford, UK – 10 October 2012: Oxford BioMedica (“Oxford BioMedica” or “the Company”) (LSE:OXB), the leading gene-based biopharmaceutical company, today announces that it plans to close the Phase II study in the United States (US) to assess the activity… Read More
Oxford BioMedica plc Board Change
— Appointment of New Non-Executive Director — Oxford, UK – 3 October 2012: Oxford BioMedica (“Oxford BioMedica” or “the Company”) (LSE:OXB), the leading… Read More
Oxford BioMedica Announces Collaboration With Immune Design Corp.
Oxford, UK and Seattle, WA, USA – 27 September 2012: Oxford BioMedica plc (“Oxford BioMedica” or “the Company”) (LSE:OXB), the leading gene-based biopharmaceutical company, has signed a master services agreement with Immune Design Corp. (Immune Design), a… Read More
Oxford BioMedica plc Interim Results for the Six Months Ended 30 June 2012
Click here to download the full 2012 interim results statement.Click here to download the 2012 interim results presentation.Click here to listen to the audio replay… Read More
Oxford BioMedica plc Interim Results for the Six Months Ended 30 June 2012
Click here to download the full 2012 interim results statement.Click here to download the 2012 interim results presentation.Click here to listen to the audio replay… Read More
Oxford BioMedica to Present at the 2012 Rodman & Renshaw Annual Global Investment Conference
— 14th Annual Healthcare Conference — Oxford, UK – 29 August 2012: Oxford BioMedica plc (“Oxford BioMedica” or “the Company”) (LSE:OXB), the leading… Read More
Oxford BioMedica Announces Positive DSMB Review of Ongoing RetinoStat® and StarGen™ Clinical Studies
— Treatment of final RetinoStat® patient cohort underway — Oxford, UK – 08 August 2012: Oxford BioMedica plc (“Oxford BioMedica”… Read More
Oxford BioMedica Plc Announces Results of Firm Placing and Open Offer
THIS ANNOUNCEMENT AND THE INFORMATION CONTAINED HEREIN IS RESTRICTED AND IS NOT FOR RELEASE, PUBLICATION OR DISTRIBUTION, DIRECTLY OR INDIRECTLY, IN WHOLE OR IN PART, IN OR INTO THE UNITED STATES, AUSTRALIA, CANADA OR JAPAN OR ANY… Read More